

Remarks

Claims 1-11, 25-29, and 31-39 are cancelled herein.

Claims 12, 24, and 30 are amended.

Claims 16-18, and 23 are withdrawn.

Claim Objections

Applicants have amended the claims so that they conform in scope to the elected subject matter. Thus, Applicants request that the objection be removed.

Claim Rejections 35 U.S.C. § 112

Claims 2-4, 12-25, 24-27, and 29 were rejected as not allegedly enabling “analogs” of prostaglandins. In amending the claims to conform to the elected subject matter, all reference to “analogs” have been removed. Thus, it is believed that this rejection is no longer applicable, and Applicants request that it be removed.

Claims 12-15, 19, and 24-29 were rejected because “prodrugs” were allegedly not enabled. The term “prodrugs” has been deleted from the claims. Thus, Applicants request that this rejection be removed.

Claims 1-8 and 11 were rejected as allegedly indefinite. These claims have been cancelled. Thus, Applicants request that this rejection be removed.

Claims 12-15 were rejected as allegedly indefinite for the term “derivative.” This term has been deleted from the claims. Thus, Applicants request that this rejection be removed.

Claims 5-8, 12-15, 19-21 and 24-29 were rejected as allegedly indefinite for use of the term “comprising” to describe the compound. This use has been deleted or the claims have been cancelled. Thus, Applicants request that this rejection be removed.

Claims 12-15, 19, and 24-29 were rejected as allegedly being indefinite because of the use of the terms “prodrug” and “ester” in the same claim. Since “prodrug” has been deleted, it is believed that this rejection no longer applies. Thus, Applicants request that this rejection be removed.

As it is believed that the amendments made herein overcome all rejections and objections, Applicants respectfully request that Examiner pass application to issue.

Please use Deposit Account 01-0885 for extension of time fees or any other fees or credits relating to this response.

Respectfully submitted,

Date: September 27, 2006

/Brent A. Johnson/
Brent A. Johnson
Registration No. 51,851
Agent of Record
Telephone: 714/246-4348
Telecopier: 714/246-4249

Brent A. Johnson (T2-7H)
Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612